Tracking Outcomes in Psychosis (TOPSY)
調査の概要
状態
条件
詳細な説明
OBJECTIVES: The objective of this study is to investigate the pathophysiology of Formal Thought Disorder and variable outcomes in the early stages of schizophrenia. In particular, investigators aim to test the hypothesis that 1. Anatomical abnormalities involving the grey matter of the Anterior Insula and Medial Prefrontal Cortex in first episode schizophrenia predicts FTD that persists by 6 months of illness 2. An excess of glutamine/glutamate, or reduction in glutathione, in Medial Prefrontal Cortex at index episode will be associated with persistent FTD 3.Aberrant connectivity between Anterior Insula and Medial Prefrontal Cortex will specifically predict the severity of persistent FTD irrespective of the stage of illness; the change in this connectivity will track the variable 3-year outcome among patients with first episode of psychosis.
METHODS: This study will employ a cross-sectional design recruiting n=126 participants from the Prevention & Early Intervention Program for Psychoses (PEPP). Four groups of participants will be assessed: patients at a later stage of schizophrenia (chronic illness group) (n=42), newly referred first episode group of PEPP patients (n=84), Clinical High Risk patients (n=60) and healthy Controls (n=45). Measurements: Patients will be diagnosed using the criteria for schizophrenia according to DSM-V(34). Demographic variables such as age, gender and parental socioeconomic status will be recorded to adjust for potential confounding effects. Patients will undergo baseline assessments to assess seven features of FTD (poverty of speech, weakening of goal, perseveration, looseness, peculiar word usage, peculiar sentence usage and peculiar logic) in line with the validated procedure for administering Thought Language Index [TLI](17). First episode patients will undergo four 7T MRI scanning sessions over the course of 2.5 years (baseline, 6 months, 18 months, 30 months)lasting for 60 minutes each, as described in our previous work (15). During this time, researchers will perform MR spectroscopy (MPFC voxel (31)), T1 weighted structural scan and eyes-closed, task-free, 6 minutes resting-state functional MRI. 6 months after the onset of first episode, the clinical assessment will be repeated using TLI. Patients with persistent FTD will be identified (from previous studies, 40% of patients are expected to have persistent FTD (9)) and separated from patients who have no FTD at 6-months time point. Patients with established illness will undergo only 2 scans: baseline and 1 year later.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Lena Palaniyappan, MD, PhD
- 電話番号:519.685.8054
- メール:lena.palaniyappan.@lhsc.on.ca
研究場所
-
-
Ontario
-
London、Ontario、カナダ、N6A 5B7
- 募集
- Robarts Research
-
コンタクト:
- Lena Palaniyappan, MBBS, PhD
- 電話番号:519-685-8054
- メール:lena.palaniyappan@lhsc.on.ca
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Study population includes two groups of individuals:
- First Episode psychotic patients: This group will contain 84 new patients enrolled in the Prevention and early Intervention Program for Psychosis.
- Chronic Patients: This group will contain 42 patients who have been enrolled in the Prevention and Early Intervention Program for Psychosis for >3 years.
- Healthy Controls: This group will contain 42 healthy controls not being treated for a major mental illness defined using DSM-V criteria.
説明
Inclusion Criteria:
- 16-45 years old
- Outpatient of the Prevention and Early Intervention Program for Psychosis
Exclusion Criteria:
- Drug or alcohol dependence in past year
- History of head injury (with associated unconsciousness for any period)
- Mental retardation or suffering from medical conditions such as untreated hypertension, diabetes, hepatic/renal insufficiency, neurological illnesses
- Otherwise unable to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:見込みのある
コホートと介入
グループ/コホート |
---|
First Episode Patients
First episode patients new to the PEPP program.
|
Chronic Patients
Existing patients who have been enrolled in the PEPP program for >3 years
|
Healthy Controls
Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
|
Cliniucal High Risk patients
Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Thought Language Index Score between baseline and 6 months
時間枠:6 Months
|
Predicting the change in TLI score based on baseline anatomical abnormalities identified through MRI
|
6 Months
|
Time to remission of positive symptoms of psychosis
時間枠:30 months
|
The time between baseline and remission of positive symptoms based on PANSS-8
|
30 months
|
Time to remission of negative symptoms of psychosis
時間枠:30 months
|
The amount of time between baseline and remission of negative symptoms based on PANSS-8
|
30 months
|
Emergence of treatment resistance using operational criteria
時間枠:30 months
|
30 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Thought Language Index score between baseline and longitudinal follow up-dates (12 months, 18 months, 24 months and 30 months)
時間枠:1-2.5 years
|
Net change in TLI score as predicted by anatomical abnormalities associated with imaging at various imaging time points.
|
1-2.5 years
|
Change in overall symptoms over time
時間枠:30 months
|
Tracking changes in scores on the PANSS-8 over the 30 months of follow up for first episode patients
|
30 months
|
Changes in myelin content
時間枠:30 months (follow up period for first episode patients)
|
Longitudinal changes in myelin content as measured using quantitative t1 images
|
30 months (follow up period for first episode patients)
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Harrow M, Marengo JT. Schizophrenic thought disorder at followup: its persistence and prognostic significance. Schizophr Bull. 1986;12(3):373-93. doi: 10.1093/schbul/12.3.373.
- Palaniyappan L, Mahmood J, Balain V, Mougin O, Gowland PA, Liddle PF. Structural correlates of formal thought disorder in schizophrenia: An ultra-high field multivariate morphometry study. Schizophr Res. 2015 Oct;168(1-2):305-12. doi: 10.1016/j.schres.2015.07.022. Epub 2015 Jul 29.
- Liddle PF, Ngan ET, Caissie SL, Anderson CM, Bates AT, Quested DJ, White R, Weg R. Thought and Language Index: an instrument for assessing thought and language in schizophrenia. Br J Psychiatry. 2002 Oct;181:326-30. doi: 10.1192/bjp.181.4.326.
- Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, Menon RS, Rajakumar N, Pavlosky WF, Densmore M, Schaefer B, Williamson PC. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011 Jun;198(6):448-56. doi: 10.1192/bjp.bp.110.079608.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) (2013).
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 10014067
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。